Maze Therapeutics, Inc.
MAZE
$41.49
$4.2211.32%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.14% | 41.82% | 27.44% | 7.19% | 19.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.33% | 43.34% | 26.37% | 28.96% | 5.95% |
| Operating Income | -36.06% | -126.14% | -26.37% | -28.96% | 3.96% |
| Income Before Tax | -20.20% | -123.92% | -0.90% | -12.33% | -1.15% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.55% | -124.22% | -0.90% | -11.30% | -0.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.55% | -124.22% | -0.90% | -11.30% | -0.02% |
| EBIT | -36.06% | -126.14% | -26.37% | -28.96% | 3.96% |
| EBITDA | -38.19% | -125.51% | -28.28% | -31.47% | 3.23% |
| EPS Basic | 93.59% | -105.06% | 21.44% | 82.43% | 4.29% |
| Normalized Basic EPS | 92.91% | -101.31% | 90.35% | -18.03% | 13.45% |
| EPS Diluted | 93.56% | -111.41% | 22.86% | 79.89% | 4.24% |
| Normalized Diluted EPS | 92.91% | -103.02% | 90.35% | -18.03% | 13.45% |
| Average Basic Shares Outstanding | 1,794.93% | 1,725.04% | 1,125.22% | 5.07% | 4.50% |
| Average Diluted Shares Outstanding | 1,794.93% | 693.47% | 1,125.22% | 5.07% | 4.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |